DanCann Pharma A/S: Pioneers in cannabinoids
DanCann Pharma A/S is a Danish biopharmaceutical company powered by cannabinoids, which comprises a consortium of companies dedicated to the commercial aspects of the EU-GxP sphere.
This includes a focus on market access, sourcing, and distribution, with a specialised emphasis on cannabinoid medicines and medications targeting the endocannabinoid system, and novel treatment modalities.
The portfolio and pipeline encompass both generic and proprietary IP products, with the aim of ensuring a comprehensive and extensive product portfolio.
DanCann Pharma A/S: Pioneers in cannabinoids
DanCann Pharma A/S is a Danish biopharmaceutical company powered by cannabinoids, which comprises a consortium of companies dedicated to the commercial aspects of the EU-GxP sphere.
This includes a focus on market access, sourcing, and distribution, with a specialised emphasis on cannabinoid medicines and medications targeting the endocannabinoid system, and novel treatment modalities.
The portfolio and pipeline encompass both generic and proprietary IP products, with the aim of ensuring a comprehensive and extensive product portfolio.
The DCP foundation:
Mission, vision, and values statements are the foundation for our strategic plan. They state the purpose, direction, and underlying values of DanCann Pharma while serving as a tool that provides us with guidance and direction.
- General
To supply relief to those given up on by the healthcare system. Condition; Unmet needs.
Our dream is about giving new hope to patients and their families who are left behind by the conventional healthcare industry, and to inspire a movement towards a better future for all.
2018
The emergence of medicinal cannabis and the birth of DanCann.
January 2018 marked a pivotal moment, conceived with the aim of enabling the legal prescription of medicinal cannabis for Danish patients.
In March 2018, DanCann was founded by Jeppe Krog Rasmussen in his childhood room, driven by a vision to make a meaningful impact for those who have been left to fend for themselves.
During June 2018, DanCann secured the first license from the Danish Medicines Agency. DanCann was among the first to be granted a license under the Development Scheme for the handling of cannabis for medical purposes.
In January 2019, a reimbursement scheme for prescribed medicinal cannabis as part of the Pilot Programme became eligible for Danish patients.
In June 2019, DanCann transitions its name from ‘DanCann’ to ‘DanCann Pharma’ to underscore its commitment to healthcare. DanCann Pharma is the abbreviation of ‘Danish Cannabinoid Pharmaceuticals’.
In November 2020, DanCann Pharma was listed on the Spotlight Stock Market in Stockholm. DanCann Pharma successfully raised DKK 30 million in new capital, with the round ultimately being oversubscribed by 183 percent, totalling approximately DKK 55 million.
In October 2021, as a strategic move aligned with its corporate vision, DanCann Pharma completed the acquisition of its counterpart, CannGros ApS. Based hereon, DanCann Pharma overtook the distribution of Bedrocan®, Bediol®, and Bedica® to all pharmacies across Denmark.
In December 2021, the future of the Pilot Programme underwent a review. The outcome resulted in an extension of the scheme for an additional four years, extending until the end of 2025. The scheme received strong support and was approved, passing with a vote of 102-0.
In November 2021, the Danish Medicines Agency conducted an inspection of DanCann Pharma's facility, BP1. DanCann Pharma obtained its EU-GMP approval on its first attempt.
In December 2022, in conjunction with the inspection of BP1 and the attainment of the EU-GMP license, CannGros also applied to relocate its repackaging facilities from Glostrup to Ansager, establishing a more streamlined and consolidated base.
In August 2023, DanCann Pharma embarked on a strategic realignment, which will leverage its established strengths. DanCann Pharma's future direction will entail a substantial elevation of its efforts in sourcing, distribution, and sales within the Danish market.
In December 2023, DanCann Pharma applied for the inclusion of a new medicine under the Pilot Programme with medicinal cannabis. The medicine is the company's first in the form of an extract for oral consumption (liquid form).
In June 2024, DanCann Pharma applied for the inclusion of two new medicines under the Pilot Programme with medicinal cannabis. The medicines include two additional forms of flos and granules, and the company's first CBD-based medicine.
In December 2024, a new subsidiary, OTC Group ApS, was established, laying the foundation for the Group’s expanded focus on OTC (over-the-counter) preparations.
In February 2025, Danish policymakers and the Ministry of Health and the Interior officially made the prescription-based medicinal cannabis scheme permanent in Denmark.
CannGros ApS - your medicinal cannabis supplier
DanCann Pharma conducts its Danish operations through its subsidiary, known as CannGros ApS, which possesses the necessary licenses for handling narcotic substances, as well as importing and distributing cannabis primary- and intermediate products respectively.
CannGros manages the importation of medicinal products and narcotics while also overseeing primary and secondary packaging, warehousing, logistics, shipping, labeling, and batch release.
CannGros maintains partnerships with the major wholesalers in Denmark, facilitating the swift delivery of its portfolio to all pharmacies across the nation.
CannGros ApS - your medicinal cannabis supplier
DanCann Pharma conducts its Danish operations through its subsidiary, known as CannGros ApS, which possesses the necessary licenses for handling narcotic substances, as well as importing and distributing cannabis primary- and intermediate products respectively.
CannGros manages the importation of medicinal products and narcotics while also overseeing primary and secondary packaging, warehousing, logistics, shipping, labeling, and batch release.
CannGros maintains partnerships with the major wholesalers in Denmark, facilitating the swift delivery of its portfolio to all pharmacies across the nation.
Associated member of:
Join the cannabinoid revolution today
We are always on the lookout for our next teammate and go through applications every day. If you find an opportunity that speaks to you, please apply and send us your resume with a few sentences describing why you believe we are a great match.